Bristol-Myers Squibb Co. v. Matrix Laboratories Ltd.

655 F. App'x 9
CourtCourt of Appeals for the Second Circuit
DecidedJune 30, 2016
Docket15-1922-cv
StatusUnpublished
Cited by13 cases

This text of 655 F. App'x 9 (Bristol-Myers Squibb Co. v. Matrix Laboratories Ltd.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bristol-Myers Squibb Co. v. Matrix Laboratories Ltd., 655 F. App'x 9 (2d Cir. 2016).

Opinion

SUMMARY ORDER

Plaintiff-Appellant Bristol-Myers Squibb Company (“BMS”), an American pharmaceutical manufacturer that owns the patent for the antiretroviral drug ata-zanavir, appeals from a judgment of the United States District Court for the Southern District of New York (Engelmayer, /.), dismissing, for a second time, BMS’s breach-of-contract claims against Defendant-Appellee Matrix Laboratories Limited (“Matrix”), an Indian generic drug manufacturer located in India and a wholly owned subsidiary of Mylan Laboratories Limited. On April 17, 2011, BMS and Matrix entered into an “Immunity from Suit Agreement” (“IFSA”), pursuant to which BMS granted Matrix the right to manufacture, sell, and distribute atazanavir within a designated set of countries (the “Territory”), with immunity from any intellectual property infringement suit by BMS. Section 3.1(d) of the IFSA, however, prohibited Matrix from “selling], distributing], or otherwise transferring] [atazanavir] manufactured [under the IFSA] to any third parties it reasonably believes may export the [atazanavir] outside the Territory where Patents exist,” J.A. 40. BMS alleges that Matrix breached § 3.1(d) twice, once in 2012 and again in 2014, when Matrix sold generic atazanavir to the Pan American Health Organization (“PAHO”), a third-party organization based in Washington, D.C., for distribution in Venezuela, which is not in the Territory.

BMS brought a breach-of-contract claim against Matrix in the United States District Court for the Southern District of New York on July 30, 2012, and filed an amended complaint on April 16, 2013. Matrix moved to dismiss pursuant to Federal Rule of Civil Procedure 12(b)(6), and the district court (Engelmayer, J.) granted the motion. Bristol-Myers Squibb Co. v. Matrix Labs. Ltd., 964 F.Supp.2d 287 (S.D.N.Y. 2013). In dismissing BMS’s first amended complaint (“FAC”), the district court ruled that, under the plain meaning of § 3.1(d), Matrix could not have breached the provision unless it sold atazanavir to a third party that was physically “present in the Territory, and therefore in a position to export the product ‘outside the [Territory.’ ” Id. at 297. On appeal, we disagreed with the district court’s interpretation that § 3.1(d) unambiguously means that the third party’s physical presence in the Territory is necessary in order for the third party to export the atazanavir from the Territory to outside the Territory. Bristol-Myers Squibb Co. v. Matrix Labs. Ltd., 586 Fed.Appx. 747, 750 (2d Cir. 2014), Rather, we noted, another potential *11 ly permissible interpretation of § 3.1(d) is that a third party may export atazanavir from the Territory within the meaning of the provision when title in the atazanavir transfers to the third party while the ata-zanavir is in the Territory. Id. at 750-51. Although we found that the FAC failed to state a claim that PAHO had exported the atazanavir from India to Venezuela, we concluded that, in light of the district court’s erroneous interpretation of the IFSA, it was appropriate to vacate and remand to allow BMS to seek leave to amend its complaint. Id. at 751-52.

On remand, BMS filed a second amended complaint (“SAC”), alleging that PAHO exported the atazanavir to Venezuela because title transferred to PAHO when Matrix delivered the atazanavir to a common carrier in India. Matrix again filed a motion to dismiss pursuant to Rule 12(b)(6) for failure to state a claim, which the district court granted. Bristol-Myers Squibb Co. v. Matrix Labs. Ltd., No. 12 Civ.5846, 2015 WL 2257705 (S.D.N.Y. May 13, 2015); see also Bristol-Myers Squibb Co. v. Matrix Labs. Ltd., No. 12 Civ. 5846, 2015 WL 4430614 (S.D.N.Y. July 20, 2015). This appeal followed. We assume the parties’ familiarity . with the underlying facts, the procedural history of the case, and the issues on appeal.

* * *

“We review de novo the dismissal of a complaint under Rule 12(b)(6), accepting all allegations in the complaint as true and drawing all inferences in favor of the plaintiff.” TechnoMarine SA v. Giftports, Inc., 758 F.3d 493, 498 (2d Cir. 2014). To survive a motion to dismiss, “a complaint must contain sufficient factual matter, accepted as true, to state a claim to relief that is plausible on its face.” Nielsen v. AECOM Tech. Corp., 762 F.3d 214, 218 (2d Cir. 2014) (quoting Ashcroft v. Iqbal, 556 U.S. 662, 678, 129 S.Ct. 1937, 173 L.Ed.2d 868 (2009)).

BMS argues that either United States law or the law of India governs the transactions between Matrix and PAHO, and that under either one, the facts pled in the SAC give rise to a plausible claim that PAHO exported the atazanavir from India because title transferred to PAHO when Matrix delivered the atazanavir to a common carrier in India for shipment to Venezuela. The district court concluded that United States law was inapplicable and also' may have concluded that BMS waived reliance on United States law. As to BMS’s statements about Indian law in its brief in opposition to Matrix’s motion to dismiss, the district court determined that the SAC provided insufficient notice of BMS’s intention to invoke foreign law. We disagree both that it is appropriate at this juncture to deem United States law inapplicable and that notice as to BMS’s intent to invoke foreign law was insufficient.

As a preliminary matter, we emphasize that BMS was not required to identify in the SAC which law was applicable to the Matrix-PAHO transactions, to which BMS was not a party. Although the law that applies to the Matrix-PAHO transactions is relevant to BMS’s argument that title to the atazanavir transferred to PAHO in India, “[fjederal pleading rules call for ‘a short and plain statement of the claim showing that the pleader is entitled to relief; they do not countenance dismissal of a complaint for imperfect statement of the legal theory supporting the claim asserted.” Johnson v. City of Shelby, Miss., — U.S. —, 135 S.Ct. 346, 346, 190 L.Ed.2d 309 (2014) (quoting Fed. R. Civ. P. 8(a)(2)). Because the heightened pleading standard in Bell Atl. Corp. v. Twombly, 550 U.S. 544, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007), and Iqbal “concern[s] the factual allegations a complaint must contain to survive a motion to dismiss,” those cases do not require BMS to identify the sub *12 stantive legal basis for its claim, much less the law that governs an agreement to which it was not a party, Johnson, 135 S.Ct. at 347.

Turning to the district court’s analysis, we first conclude that, to the extent that the district court may have rejected BMS’s reliance on United States law on the ground that BMS conceded the inapplicability of such law, the district court erred.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
655 F. App'x 9, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bristol-myers-squibb-co-v-matrix-laboratories-ltd-ca2-2016.